An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Ixazomib (Primary)
- Indications Amyloidosis; Lymphoma; Multiple myeloma
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 04 Apr 2017 Status changed from not yet recruiting to recruiting.
- 01 Nov 2016 Planned initiation date changed from 1 Oct 2016 to 1 Dec 2016.
- 07 Oct 2016 New trial record